Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary
August 5, 2021
Earnings Call Speaker Segments
Diane Weiser
executiveGood afternoon, and thank you all for being with us on today's call. Robert Blum, who serves as our President and Chief Executive Officer, is going to kick things off with a look at the quarter and what's happened recently. After that, Fady Malik, our EVP of Research and development, will give an update on omecamtiv mecarbil, covering the secondary analyses from GALACTIC-HF, our positive Phase III clinical trial of omecamtiv mecarbil, along with recent interactions and next steps with the FDA. After that, Andrew Callos, who serves as our EVP and Chief Commercial Officer, will provide a status report on the go-to-market approach for omecamtiv mecarbil, along with how those initiatives tie into our franchise development efforts and our upcoming commercialization plans for Aficamten, also known as CK-274. Next, Stuart Kupfer, our SVP and Chief Medical Officer, will bring everyone up to speed on the Aficamten development program, focusing on the recently disclosed findings from REDWOOD-HCM, our successful Phase II clinical trial. Next, Robert Wong, who serves as our VP and Chief Accounting Officer, will provide a rundown of the finances from the quarter just ended. Then Ching jaw, our SVP and Chief Financial Officer, is going to discuss what we expect financially and our approaches to corporate development. After that, Robert Blum will return to share some closing remarks along with the milestones we anticipate for the rest of 2021. I want to note that certain portions of what we cover next, including how we answer your questions, will include statements tied to upcoming events and results instead of things that already happened, which means they qualify as forward-looking statements. The outcomes we actually achieve could end up differing substantially from what those forward-looking statements anticipate. You can find more details about the things that might make what actually happens differ significantly from what we've projected in these forward-looking statements in the documents we file with the SEC. That includes the 8-K we submitted covering our financial results for the second quarter of 2021. We're not committing to revise any of these forward-looking statements once today's call wraps up. At this point, I'll hand things over to Robert.
Robert Blum
executiveThanks, Diane, and I appreciate all of you being here on today's call. The second quarter was a productive one for us, and things have only picked up pace since then, as we've hit a number of milestones spanning both our cardiovascular and neuromuscular development programs. Over the last several quarters, we've achieved enormous strides on the clinical development side, highlighted by favorable Phase III data from GALACTIC, encouraging Phase II findings from Redwood HCM, finishing enrollment for METEORIC-HF, and launching COURAGE-ALS, the Phase III study of reldesemtiv in ALS patients. As we look ahead, we're getting ready for our first NDA filing and performing strongly on our commercial readiness goals, while simultaneously moving forward 3 separate late-stage development programs, all of which should be in Phase III clinical trials by the fourth quarter. That's an outstanding accomplishment for any organization, let alone a company of our size, yet it speaks to our focus, our innovation, our resilience, our resourcefulness, and our disciplined strategic corporate development. Notably, momentum throughout our pipeline also drove our recent equity offering, which strengthened our balance sheet and should leave us with more than $600 million at year-end. That gives us a solid financial footing as we move through key milestones in building a sustainable and durable business rooted in our industry-leading muscle biology focus. As Fady will explain in more detail, new analyses from GALACTIC-HF bolster earlier findings, reinforcing that patients with elevated risk factors, indicating more severe heart failure, gained greater treatment benefit from omecamtiv mecarbil when combined with standard of care, and these results bode well for a clearly defined, identifiable target patient population. These patients are still among the hardest to treat even with guideline-directed medical therapy available, and given ongoing input from the health care professional community, we think omecamtiv mecarbil could address an unmet need within the treatment armamentarium. As you'll hear more about in the coming months, we've had several further interactions with FDA as we pursue our goal of submitting an NDA for omecamtiv mecarbil in this second half of the year. At the same time, under Andrew's leadership, our commercialization strategy continues to take shape. We have active work streams moving forward across every element of our go-to-market strategy, including product positioning, market research, value proposition development, market access, and manufacturing and other logistics scale up. Shifting to another underserved cardiovascular patient population, we were glad to report top line results from REDWOOD-HCM, which matched our high expectations for this dose-ranging trial and our next-in-class objectives. Having led the way in understanding how to modulate cardiac myosin, it's gratifying to witness the physicochemical characteristics we chose to emphasize while optimizing Aficamten producing clinically significant outcomes for patients; now that we have favorable data from Redwood HCM, constructive FDA input has come our way following our recent Type C and end of Phase II discussions, which supports moving ahead into our Phase III study planned to begin in Q4 of 2021, with eager trial locations throughout North America and Europe, we expect strong enrollment interest, and we'll share updates once the trial is up and running. And last, given a clear path for submitting omecamtiv mecarbil along with encouraging Redwood HCM results that back a Phase III study and a stronger balance sheet, earlier this week we revealed the launch of COURAGE-ALS, our Phase III clinical study of reldesemtiv in ALS patients. Also, as a reminder, per the terms of our revised collaboration deal with Astellas, Cytokinetics now holds development and commercialization rights for reldesemtiv, and Astellas will put $12 million toward running this trial; we consider ourselves lucky to be at a pivotal moment in our company's evolution. The potential of modulating contractile proteins that power muscle contractility is coming to fruition through our successful clinical programs, and we thank our shareholders for their continued faith in what this platform can achieve, enabling us to bring patients first-in-class and next-in-class drug candidates that could enhance both their health span and overall quality of life; with that said, I'll hand the call to Fady to go over recent developments regarding omecamtiv mecarbil.
Fady Malik
executiveThanks, Robert. You're right that the results from additional GALACTIC-HF analyses we presented during this quarter at Heart Failure 2021, a congress of the European Society of Cardiology held internationally, continue to build on what we found before. They show that patients who have signs of more severe heart failure and are at greater risk gain more clinically from treatment with omecamtiv mecarbil alongside standard of care. Specifically, we report findings from analyses involving individuals with a higher baseline NT-proBNP, and also those with severe heart failure as defined by adapted criteria from the Advanced Heart failure position statement of the Heart Failure Association of the European Society of Cardiology. Even though guideline directed medical therapy is available and adhered to, a large number of severe heart failure patients stay at high-risk for meaningful clinical events. And on the basis of this data, omecamtiv mecarbil could deliver a fresh treatment choice for more severe heart failure patients who have exhausted standard of care yet remain out of hospital. As I have stated previously, these findings fit nicely with how omecamtiv mecarbil works, in that its capacity to enhance cardiac function and performance seems to influence outcomes among patients who show signs that their cardiac function is especially constrained. Hearing prominent experts voice this perspective has been both rewarding and encouraging, especially given that the greatest unmet need involves the very patients who stand to gain the most from omecamtiv mecarbil. More precisely, we've been told that these results open a door to spotlighting a specific group of individuals who might benefit from treatment with omecamtiv mecarbil should it be an option. According to the many doctors with whom we've consulted, few alternatives exist for such patients. And if it secures approval, omecamtiv mecarbil could serve as an essential addition to today's standard of care, owing to how it works and the fact that it has no negative effect on hemodynamics or kidney function. METEORIC-HF is our second Phase III study for omecamtiv mecarbil. Its goal is to deepen what we know about how the drug's benefits work. The idea is that if a candidate therapy improves systolic function, patients might gain greater exercise capacity and stamina, which could help them participate more in the things they enjoy each day, and we may be able to demonstrate that. During the second quarter, enrollment for METEORIC-HF was completed, even with the difficulties created by the pandemic, and we expect to finish running the trial by the end of the year. If that happens, we could share results during the first part of 2022. Let me now discuss the regulatory situation. Starting at the beginning of this year, we participated in three meetings with the FDA that went well. One was a top line meeting where we reviewed and got feedback on the initial findings from GALACTIC-HF. Another was a Type C meeting, which let us go into detail about the important elements of the GALACTIC-HF results and how omecamtiv mecarbil would be used, and this helped guide how we would approach submitting an NDA. Then there was a pre-NDA meeting where we went over the results — actually, more the specifics of the submission, things like what would be in it and how the data sets would be formatted. Overall, all of these sessions were productive, with plenty of discussion, and they achieved our goals — they helped shape what goes into the NDA we plan to file as well as how it's put together. We're still on schedule, continuing to push toward filing that NDA during the back half of this year, drawing on the GALACTIC-HF findings along with the broader development effort—more than 30 clinical trials—and shaped by the regulatory conversations we've had for a long time. At the same time, we're in talks with FDA about our approach to make personalized dose optimization possible for patients on omecamtiv mecarbil, with the aim of having it ready should approval come, using the strongest available technology and a centralized method for gathering and processing samples and for getting patient data into physicians' hands. We're eager to share more about this approach for optimal personalized dosing down the road. As we get nearer to our objective of filing the NDA with FDA for possible approval of omecamtiv mecarbil, our expanding group of medical science liaisons is out there educating hospital-based and community cardiologists about the difficulty of impaired contractility in heart failure patients with reduced ejection fractions, and we stay dedicated to helping physicians deepen their grasp of the sarcomere in cardiac muscle function. On top of that, we've advanced in building a framework for an investigator-sponsored study program. And we anticipate shedding further light on what omecamtiv mecarbil could offer within the treatment armamentarium; with that, I'll hand the call to Andrew to go deeper on how the go-to-market strategy for omecamtiv mecarbil is progressing.
Andrew Callos
executiveAppreciate that, Fady. Through Q2, our Board gave the nod to the go-to-market plan we put forward for omecamtiv mecarbil, and from that point on we've been moving ahead with putting it into practice while getting ready for a possible commercial launch in 2022. At an Investor Day later this year, we intend to offer a deep dive into that strategy and how it connects with our cardiac muscle franchise approach and the planning we're doing for Aficamten's commercial launch. For now, though, I'll walk through several progress highlights. On the organizational development side, beyond the outstanding team I came into, we're growing the commercial organization across every level, bringing on key people in marketing, health economics and outcomes research, analytics, supply chain and logistics, and market access. Beyond that, I expect the complete leadership team to be seated by the time summer ends. As Fady told you, findings from GALACTIC-HF plus the secondary analyses make clear which subset of heart failure patients sees the most concentrated benefit from omecamtiv mecarbil: those whose ejection fraction sits below 30, or who are no longer able to tolerate guideline directed medical therapy because of renal or blood pressure impairment, or who were hospitalized recently. The patients likely to gain the most from omecamtiv mecarbil account for 50% — roughly 50% of all heart failure with reduced ejection fraction patients. What's more, our market research confirms these patients are handled by under 30% of total cardiologists and at under 15% of total U.S. hospitals that treat the bulk of these severe cases. Aiming at this clearly defined, hard-to-reach subset of cardiologists and hospitals also lets us launch effectively with a sizable specialty cardiology field force. It's worth noting there's also substantial overlap between heart failure and ATM directed accounts. To be specific, roughly 1,100 high-value hospitals and centers of excellence treat both patient populations, so the cardiac muscle directed field force we're assembling now is purpose-driven to leverage the infrastructure and relationships we built in support of omecamtiv mecarbil or Aficamten in 2 to 3 years. Simply put, we expect our reps to carry another product in their bag without any need to build an independent field force. On top of that, we recognize and appreciate how heavy the cost burden of heart failure is, since it stands as the most common hospital admission diagnosis for Medicare, and hospitalizations and readmissions run considerably higher among patients with lower ejection fraction. As you may know, these are the patients who turn into frequent flyers in hospitals, given their increased risk of rehospitalization with every subsequent hospitalization event. Because evidence from GALACTIC-HF shows the risk reduction from omecamtiv mecarbil was greatest among patients with lower ejection fraction levels, we're evaluating the cost effectiveness potential for patients potentially treated with omecamtiv mecarbil. Last of all, our work with payers will be critical to ensuring patients have access to omecamtiv mecarbil. Right now, the reimbursement picture for heart failure breaks down to roughly 55% Medicare Part D and about 30% from commercial payers. We've kicked off conversations with payers, engaging a number of these major stakeholders, and they're gaining a clearer picture of what shapes their choices when it comes to heart failure, especially as they weigh a range of new branded treatments for this group of patients. Along those lines, we're putting together a separate value story grounded in what came out of GALACTIC-HF, and we think a clearly defined group of patients dealing with severe heart failure will be received well by payers; with that said, I'll hand things over to Stuart for a update on Aficamten and the next steps in the cardiac myosin inhibitor development program.
Stuart Kupfer
executiveThanks, Andrew. Today's press release covered this, but to repeat: during the quarter we received final approval from the World Health organization and The United States Adopted Names for Aficamten as the international nonproprietary name for CK-274. About three weeks ago, we announced positive top line results from cohorts 1 and 2 of REDWOOD-HCM, our Phase II clinical trial of Aficamten. Since we already held a dedicated conference call to report those results, I'll skip the details and instead give a quick recap of the key data, then turn to next steps as we work toward opening a Phase III clinical trial by the end of this year. The REDWOOD-HCM trial's top-line findings showed that after 10 weeks of Aficamten treatment, there were highly statistically significant decreases from baseline versus placebo in the average resting and post-Valsalva left ventricular outflow tract pressure gradients across both cohort 1 and cohort 2. In cohort 1, where a lower dose range of 5 to 10 milligrams was tested, 79% of Aficamten-treated patients hit the treatment target goals — resting gradient under 30 millimeters of mercury and post-Valsalva gradient under 50 millimeters of mercury at week 10 — versus 8% on placebo. When it came to cohort 2, where the dose range tested was higher, between 10 and 30 milligrams, the target goal was reached by 93% of those given Aficamten. For patients on Aficamten, reductions in both resting and post Valsalva gradients showed up by week 2, and the largest treatment effect came at week 6, once dose titration had been completed; that effect held steady all the way to the final visit at week 10. Aficamten was generally well tolerated as a treatment. Between the treatment arms, adverse event rates were comparable. Nothing serious in the way of adverse events was linked to Aficamten, and among those on the drug, no treatment interruptions took place. One thing we were glad to observe: just a single patient had a temporary drop in left ventricular ejection fraction below 50%, and while that called for adjusting the dose, treatment was never stopped. On the whole, the trial investigators have given us feedback that is strongly favorable and full of enthusiasm. This reflects how large the treatment effect was, how many patients met the response criteria, and the safety and tolerability profile we saw. During the quarter, we started the open-label extension portion of REDWOOD-HCM, which is still signing up patients from cohort 1 and has begun enrolling those from cohort 2. This study's main goal is to look at how safe Aficamten is over the long term, and its secondary goals center on measuring how much the gradient goes down and how the drug behaves in the body when given for a long time. We're also running a cardiac MRI sub-study to look at shifts in the heart's structure, how well it works, and fibrosis. Those enrolled in the open-label extension will start on the smallest dose, 5 milligrams, and each person's dose will be adjusted individually to hit target gradients, based on what we learned from cohorts 1 and 2. A quick reminder for everyone: cohort 3 of REDWOOD-HCM is still going. That cohort is made up of patients taking Aficamten who are also on disopyramide as background therapy. The insights gained from this cohort are going to inform the way we bring that small but meaningful patient population into Phase III. Our launch of the Phase III clinical trial for Aficamten in obstructive HCM is moving along at a brisk pace toward the fourth quarter, and the work we began last December—once the interim analysis data for cohort 1 from REDWOOD-HCM became available—continues to be carried forward. During the second quarter, a Type C meeting took place with the FDA so that our Phase III trial plan could be reviewed. The design, the endpoints and the patient populations were all discussed at that meeting, and the feedback received gave us the ability to keep moving Phase III forward as planned. Following up on the productive Type C meeting, we just received input from the FDA coming out of our end of Phase II discussion. The agency examined the final doses we selected for Phase III — those being 5, 10, 15 and 20 milligrams — as well as our plan to continue individualized dosing guided by echocardiogram, and it gave its agreement to our approach for titrating doses. In addition, we received helpful guidance on additional elements of the broader development effort, including nonclinical safety, clinical pharmacology and the format the agency prefers for data sets, along with several other areas. On top of that, we kicked off talks with the EMA this quarter, got their input, and used it to guide the design we put forward for our Phase III trial; coming up this quarter, we anticipate additional discussions with HTAs that will help us refine how we approach this program across Europe. Separately, under our partnership with Ji Xing Pharmaceuticals, during Q2 Ji Xing continued bringing patients into a Phase I trial of Aficamten in China and positioned itself to join the Phase III study of Aficamten for obstructive HCM. As we finish getting ready for a Phase III study and continue our clinical development work on Aficamten, we are currently evaluating what the optimal route looks like for a study involving patients who have non-obstructive HCM, and we anticipate clarifying our strategy before this year ends. Also, as we have previously stated, in addition to investigating the possibility of targeting hypercontractility in both obstructive and nonobstructive HCM, we believe there exists a group of heart failure patients with preserved ejection fraction whose condition is primarily caused by left ventricular hypercontractility and hypertrophy. There's also a chance that an improved next-generation cardiac myosin inhibitor could help those patients, and as the development program moves forward, we remain eager to go after this group. At this point, I'll pass it to Robert Wong for an update on our financials.
Robert Wong
executiveThanks, Stuart. First off, I'll give you an update on cash, revenue, and spending, and after that Ching will walk through our financial outlook, the revised guidance for 2021, and corporate development strategies going forward. You can find more detail on our actual second quarter 2021 results in the press release we put out earlier this afternoon. We closed the second quarter with roughly $424 million in cash and investments. Revenue for Q2 2021 came mainly from our strategic alliances with Amgen and Astellas. R&D expenses for the second quarter of 2021 rose to $36.4 million, compared with $21.8 million in the first quarter of 2020, largely because of transition costs tied to ending our collaboration with Amgen, the purchase from Amgen of about $7.3 million in materials, including manufactured quantities of active pharmaceutical ingredients for omecamtiv mecarbil, and greater spending on clinical development activities for our cardiac myosin inhibitor programs. Over 70% of R&D expenses are attributable to our cardiovascular program, which is what we expected given the activity around the Amgen transition, METEORIC-HF, and the cardiac myosin inhibitor programs, while the rest of our expenses were attributable to our early research and skeletal activity. G&A expenses for the second quarter of 2021 were $21.2 million, up from $14.2 million in Q2 2020, driven by higher personnel-related costs, including stock-based compensation, and higher commercial readiness spending. And now Ching will review our financial outlook and corporate development strategy.
Ching Jaw
executiveAppreciate that, Robert. Like Robert mentioned, we closed out Q2 with roughly $424 million in cash. On top of that, we just brought in about $297 million via an equity offering, after subtracting expenses. So as it stands on a pro forma basis, we're holding around $721 million today, and that gives us over 3 years of runway when you apply our updated net cash utilization guidance of $195 million to $215 million for 2021. That updated guidance factors in roughly $35 million of nonrecurring costs tied to new building construction, and it also assumes we receive $45 million under the funding agreement we have with RTW Investments. The net proceeds from the equity offering are going to back the Phase III clinical trial of Aficamten in patients who have obstructive HCM. Broadening the Aficamten clinical development program into additional indications, the commercial launch activities we've planned for omecamtiv mecarbil, running COURAGE-ALS — the Phase III trial of reldesemtiv in ALS patients that is now underway — plus research and general corporate purposes, working capital included. In Q2, we also moved forward on our twofold corporate development strategy: first, pursuing potential royalty monetization and/or structured financing deals to further back the commercial launch of omecamtiv mecarbil and keep developing Aficamten. Second, finding a development and commercialization partner for omecamtiv mecarbil and Aficamten in geographies that complement the ones where we plan to go to market on our own. On partnerships, our priorities center on Japan, aiming to lock in a deal that bundles omecamtiv mecarbil and Aficamten to help co-fund life cycle management studies along with regulatory and commercial activities, respectively. We'll also concentrate on China to land a possible licensing agreement for omecamtiv mecarbil, and selectively on Europe and other markets to strike potential agreements with partners for co-development and co-commercialization of omecamtiv mecarbil. Because of this, we anticipate keeping North American rights, and possibly European rights, for development and commercialization. I'm happy to say our interactions so far have been encouraging and productive in pushing these strategies ahead, and we're eager to keep those conversations going, which could lead to a deal or deals during the back half of the year. Cytokinetics has consistently secured capital by way of a wide variety of deal structures, and we still believe our route to commercialization, sustainable cash flows, and profitability will come through continuing to monetize our leadership in muscle pharmacology by doing deals. With that said, I'll hand the call back to Robert Blum.
Robert Blum
executiveThank you, Ching. As our attention turns to the rest of 2021 and the milestones ahead, I find myself thinking back to the vision we set out over 20 years ago. Back then, the majority of pharmaceutical and biotechnology firms were pulling back from cardiology research, while Cytokinetics took a fearless path, pursuing a discovery platform and biology grounded in a novel scientific rationale. That vision is now sharper than ever, as we keep intensifying our focus on the cardiovascular pipeline, with 2 drug candidates directed at muscle biology moving forward and several more not far behind. At the same time, we keep advancing our neuromuscular vertical, guided by clarity on the regulatory, clinical, commercial and financial fronts. Alongside the clinical, regulatory and commercial strides we took during the quarter for omecamtiv mecarbil, we managed to secure multiple agreements that help move the programs for omecamtiv mecarbil and CK-136 from Amgen over to Cytokinetics, one of which covers the sale and our acquisition of roughly 2 tons of omecamtiv mecarbil active pharmaceutical ingredient. As you might expect, the transition work that follows a 15-year collaboration demands a great deal of time and focus. I want to express my gratitude to the many colleagues who have thrown themselves into this effort, as we have taken on additional responsibilities and expanded our teams across the past 6 to 9 months. Turning to neuromuscular, we are likewise happy that COURAGE-ALS is now underway, and we feel its design draws on important lessons from FORTITUDE-ALS, our Phase II clinical trial of reldesemtiv in patients with ALS, along with what we have learned about the dynamics of ALS therapy development and the pressing needs of the patient community. Since greater efficacy was observed in patients whose disease appears to progress more rapidly, we believe the design of COURAGE-ALS is itself enriched toward that patient population as a result. Beyond that, informed by input from patients and caregivers and advocates and payers, as well as health care professionals, the design of COURAGE-ALS includes key elements meant to eliminate major obstacles to taking part in clinical trials, among them our inclusion of remote clinic and home nursing visits and mobile app-based endpoint measurements. Just as importantly, we are striving toward a goal of giving continued access to reldesemtiv for patients who finish COURAGE-ALS, and also for patients who took part in our earlier ALS trials. The program is being developed with the aim of ensuring ethical and equitable access. We completely understand the urgency of delivering new medicines to people living with ALS, and we are working hard with purpose, passion and compassion; to sum up, we anticipate that the coming 12 to 18 months could prove even more transformational for Cytokinetics. With 2 positive late-stage trials for our lead cardiovascular programs, we look forward to pushing ahead toward our goal of NDA submission for omecamtiv mecarbil for the potential treatment of heart failure with reduced ejection fraction, and also to launching a Phase III clinical trial of Aficamten in patients with obstructive HCM. Combined, these drug candidates could transform how these serious cardiovascular conditions are treated by leveraging myosin modulation, thereby giving patients fresh optimism. Let me now go over the milestones we anticipate for 2021. Regarding omecamtiv mecarbil, our plan is to file an NDA with the FDA during the latter half of 2021, and we anticipate finishing the METEORIC-HF trial by the end of the year, with data readouts anticipated in early 2022. As for Aficamten, we plan to launch a Phase III study of Aficamten in obstructive HCM patients during the fourth quarter of 2021. When it comes to reldesemtiv, we intend to keep enrolling patients in COURAGE-ALS across all of 2021. And on the research front, we look forward to moving programs ahead and running IND-enabling work with 1 to 2 possible drug candidates for the rest of 2021. And operator, at this point, please let's take questions from the line.
Jason Butler
analystStarting off, regarding the feedback you've received from regulators on omecamtiv, could you describe the analyses involving patients whose baseline ejection fraction was lower and what you intend to put forward for inclusion in the label? Then, moving to the second question about 274, could you discuss any regulatory interactions outside the U.S. that have taken place or are being planned? More specifically, in what way do you believe enrolling patients from China could assist with both recruitment and the conversations with regulators there?
Robert Blum
executiveAll right. To break that down, we'll begin with omecamtiv, and you raised a question concerning what we intend to do. Naturally, certain aspects of this I won't be able to address during this call. That said, I can share that given GALACTIC-HF turned out to be a positive clinical trial, our expectation is that the indication we would put forward to FDA would encompass those patients who took part in the study. However, getting to what you specifically asked about what might potentially be included in the label from those data, the emphasis would fall on those patients deriving the greatest benefit. And in our view, there is plenty of precedent among drugs already approved for heart failure when it comes to including data, particularly since in our situation it was prespecified for those subpopulations appearing to fare better than the rest. Hopefully that addresses your first question. As for your second one, I believe it concerned CK-274 and what we have planned on the regulatory front outside the U.S., correct?
Jason Butler
analystPrecisely, correct.
Robert Blum
executiveRespondent (Robert I. Blum): That is a thing that's starting, and I would call it continuing — given that those conversations are still taking place, I don't believe we're able yet to be that clear-headed and conclusive regarding it. Fady, is there anything you'd like to add?
Fady Malik
executiveMy take is that we intend to run the Phase III trial beyond North America — which of course takes in Europe and China as well — and talks with regulators to make that possible are already in progress.
Robert Blum
executiveYeah, and regarding what you asked about China, what we anticipate is that, thanks to the partnership we have with Ji Xing, they'll be prepared to move forward, which will let them enroll patients there as part of that very same global registration program and pivotal study.
Dane Leone
analystI'll be quick. I just want to ask, regarding the FDA talks about omecamtiv, it seems you're likely proceeding with the filing before you have METEORIC results. Will that eventually be folded into what you submit? Or do you think it isn't really pertinent to the label you're seeking approval for from the FDA right now?
Robert Blum
executiveThat's a fair question. Our view is that the filing can rely on GALACTIC by itself, and since METEORIC might yield additional information — and that data won't arrive until 2022 — we could at that point look at whether, possibly after omecamtiv has been approved, the label could later be broadened to include it, which would bring in findings related to omecamtiv from METEORIC-HF, but our approach is anchored in GALACTIC-HF.
Carter Gould
analystRobert, it's wonderful to witness all this advancement. I suppose we have 2 questions. To start, previously you mentioned a difference existing between your Phase III study and EXPLORER. Given that those FDA meetings have now taken place, is that distinction still valid? Also, would it reach beyond possibly adding that population into cohort 3 of REDWOOD? And then, when we consider at last getting a view of the REDWOOD data presentation at a medical meeting coming up, could you provide a bit more detail regarding which additional incremental analyses may appear during those forthcoming medical presentations?
Robert Blum
executiveCertainly. I'll hand things to Fady, who might in turn pass to Stuart, though I will note that after having a couple of interactions now with FDA concerning CK-274, it feels confirming regarding our Phase III trial strategy, and Fady plus Stuart can continue from there.
Fady Malik
executiveYeah. I mean, for Phase III, our trial design is definitely going to take lessons from what was done with omecamtiv and EXPLORER, though other aspects will set ours apart, and we'll go into more detail on that later this year. I think we definitely have alignment with FDA on our intended path forward for Phase III, and perhaps Stuart could say something about what we may plan to share at a future medical meeting concerning REDWOOD.
Stuart Kupfer
executiveSure, we definitely intend to share more about the findings we announced in that recent press release. We'll provide specifics on things like our baseline characteristics, biomarkers, pharmacokinetic data, and NYHA class, to give just one example. So you can expect additional interesting data coming. Appreciate the question.
Salim Syed
analystRobert, regarding CK-274, I had a few things I wanted to ask. Bristol received a question during their call about CK-274 compared with Mavacamten. It's interesting to me — according to them, no differentiation exists between those 2 molecules. How are you folks looking at this? Given all the published EXPLORER data plus whatever you've observed with CK-274, how sure are you that this molecule truly is differentiated? Also, is there anything within the Phase III dataset you generated that might shift that view? My second question concerns myosin inhibition more broadly. If Mavacamten were to receive an adcom, how do you think that would play out — net-net negative or positive? Do you anticipate one happening? Or what's your general thinking there?
Robert Blum
executiveSure; those are really good questions. Let me begin, then check with my colleagues whether they'd like to chime in; our belief — we hold it strongly — is that these molecules are differentiated. Indeed, absent that belief, Aficamten wouldn't be going into Phase III. We've confirmed this; so it isn't merely our internal view, it's also been confirmed through discussions with Key Opinion Leaders and investigators working in this area; yet I can understand a perspective suggesting the REDWOOD data look comparable. What I'd emphasize is our belief that certain qualities were deliberately built into CK-274, or Aficamten, such as faster onset of activity, allowing simpler and better dose titration, plus quicker reversibility. Such qualities make possible, when running later clinical trials, the inclusion and exclusion of patients. They support a trial design capable of pushing the category and the field forward — if we doubted that these next-in-class molecule properties accomplished that, we wouldn't be positioned to invest here as we anticipate could be advancing the field. So today we can't detail what those features will be or how they'll perform in a Phase III trial; but you'll find out soon. Once we announce this study's start, we'll discuss the clinical trial design, and hopefully things will become clearer. I think that covers your first question. For your second one, could you remind me?
Salim Syed
analystYeah. Regarding the Mavacamten advisory committee, would you see that as a downside or an upside if one were ever to happen?
Robert Blum
executiveSure, let me hand it over to Fady, perhaps to address that.
Fady Malik
executiveYeah. Honestly, I'd rather not guess about whether an adcom happens or not. That call belongs to the FDA, and it hinges on what was submitted. So — we'll simply have to wait and find out whether they choose to hold one.
Robert Blum
executiveNo one has floated the idea of an adcom so far. Clearly, we aren't building that into our assumptions; however, should one happen, we will definitely be ready to watch closely and consider how it could shape our planning too.
Chad Messer
analystTo start, congrats on sticking with all these programs — it's wonderful to see that you have no fewer than three promising programs going, so to speak, and they might deliver major help for patients, and none of them has had an easy road. Just a few questions about reldesemtiv. You're advancing into Phase III with it, and that's very exciting. How has the ALS community reacted, since they've been waiting quite a while for news on this — so have we all, but patients probably with the most anxiety. And could you also talk about what you took away from FORTITUDE that you believe will raise the odds of success for the trial we're referring to as COURAGE? Is that correct — the Phase III trial?
Robert Blum
executiveSure. I'll handle the first portion of that question, and I'll have Fady address the second portion; regarding how the ALS community responded, I have to admit the community was puzzled by the gap between when FORTITUDE-ALS results were announced and when we began COURAGE-ALS, because, if you remember, at the time those findings were disclosed, people described them as being among the most encouraging Phase II data ever observed in ALS, and since that was a large international placebo-controlled study, it produced fairly positive data that supported moving into Phase III. However, as we promised shareholders, we needed to be sure that prior to taking reldesemtiv into Phase III, we completed several things first; we needed to talk over those results with FDA and also with payers, in both the U.S. and in Europe; we needed to talk over a clinical trial design that would allow some peeks at the data and would allow an interim stop for futility, if that appeared suitable; and the second interim later on could also permit expanding the study if that seemed justified. We needed to grasp the study's cost, and we needed to renegotiate our collaboration agreement with Astellas so they would let us lead in this area and also co-fund that trial. We successfully negotiated both of those items. We needed to best grasp what patients would want when taking part in a clinical trial. Because, as you probably know, the ALS trial landscape has gotten more crowded, which is positive, but even so, we needed to be sure we could enroll our study quickly and know we'd have the patient community's backing. As it turns out, over these last couple of years, while we were evaluating these matters, the ALS community, led by certain advocacy groups, has grown far more assertive and engaged. That's a good thing. At the same time, they've been looking at and weighing which studies would be the most suitable for patients to join. I'm very happy to be able to report today that I AM ALS, one of the advocacy organizations that does provide ratings for clinical trials, awarded our study COURAGE-ALS its top score. And only a few trials carry that 5-star rating. They examine this design with an eye toward what serves patients best, and they rated it among their highest ever clinical trials. So all of these things we wanted to have in place before launching this trial so that we could be sure to complete what we began and do so in a way that gives the drug and patients the best chance for success here. And I believe we accomplished that well. And so, we've now begun courage ALS. Having said that, I'll hand it over to Fady to address the second part of your question.
Fady Malik
executiveThanks, Chad. Regarding how COURAGE was put together and why it might stand a better chance of working. I believe you need to go back to how we ran FORTITUDE, which you brought up at the start, FORTITUDE was a fairly large trial in ALS. More than 450 patients were enrolled in it. We saw, I think, strong hints of a slower rate of decline on both the primary endpoint of that Phase III trial, the ALSFRS, and on slow vital capacity. Those hints grew stronger when you examined the patients who entered the trial and were declining faster than the rest. So when we designed COURAGE, just as others in ALS are now doing, we concentrated on enrolling patients whose disease might be advancing more quickly, along with other measures we took, and the design is meant to maximize, in our view, the odds of success; so we're quite encouraged, given both what FORTITUDE-ALS showed before and the way we carried it out in COURAGE.
Robert Blum
executiveLooking at things through the lens of our portfolio, it was also essential for us to recognize that as reldesemtiv moves ahead in ALS, that effort is happening at the same time our pipeline of new cardiovascular therapies is progressing. So with omecamtiv mecarbil continuing to advance, and Aficamten continuing to advance as well, our view is that this supports pushing reldesemtiv forward in important respects, and it likewise serves the goal of spreading product development risk across a diversified set of programs, while ideally also maximizing the potential value we can deliver to shareholders.
Chad Messer
analystOkay, that's great, thanks. I'm grateful for the responses regarding Aficamten, and congratulations once more on reaching this point with all three of the major programs plus the other items you have underway.
Lee Hung
analystRobert, I just want to make sure I understand Jason's earlier question about omecamtiv mecarbil. Is your aim a broad label, or do you anticipate the label will zero in on the more severe patients, particularly naming those with a lower ejection fraction?
Robert Blum
executiveRight. Once more, I won't go into that much detail about our strategy, but it seems reasonable to state that we intend, our goal is, to pursue a broader label, yet one that would likewise encompass those data and results that point to where the effects are at their greatest. And by doing so, give physicians additional information to help steer therapy.
Lee Hung
analystAll right. Could you share what feedback the FDA gave during the Type C and pre-NDA meeting regarding your strategy for filing the NDA based on the GALACTIC data? Did they express any resistance to concentrating on patients with more severe disease? Did they indicate that further clinical studies may be required? Or does it appear they fully agree that the data you have is enough?
Robert Blum
executiveThose are good questions. Given the several exchanges we have had with the FDA during this year, we feel we have received the input necessary to back up my earlier statement — namely, our belief that this submission ought to center on GALACTIC-HF along with the results and data I am pointing to, especially encompassing those patients who could gain the greatest benefit.
Emanuela Branchetti
analystYou may have covered this already, but could you tell us what kind of input the KOLs gave you about the findings seen with REDWOOD, possibly concerning how it stands apart from Mavacamten and what they anticipate regarding the design and the target population for the Phase III trial that's coming up?
Robert Blum
executiveOf course. To be precise, what you're asking about is the input we've gotten on Aficamten and the way it could pave the way for Phase III.
Emanuela Branchetti
analystThat's right.
Fady Malik
executiveYeah. When we shared these findings with the steering committee, we hadn't — clearly, because they haven't been shown on a wider basis, our focus stayed on the people who took part in the trial. They were genuinely pretty happy with the characteristics of what we observed — how many responded, how large the effect was, signs that it can be reversed, and the safety profile in general that showed up in the Phase II trial. I believe each of those elements supports the design we're going to put in place for Phase III, which, like I mentioned, we'll lay out down the road; but on the whole, the reaction was very enthusiastic.
Emanuela Branchetti
analystUnderstood. Understood. Moving on to reldesemtiv now. It's encouraging that the drug is kicking off the pivotal trial on schedule. I realize it's early days, but I was hoping for a bit more detail on when you expect enrollment to happen. I noticed that remote visits were built into the design. So I was simply asking, given what you've seen with enrolling ALS patients, whether you think COVID-19 will affect this study; and when do you anticipate the interim analysis taking place?
Fady Malik
executiveOkay, I'll begin. I'll hand things to Stuart in a moment. But in my view, it's much too soon to guess at the trial's timing. We are only now beginning to screen patients. Sites are still being brought online. Once enrollment speed becomes visible, perhaps we can offer improved estimates for the timing. Stuart, anything you'd like to add?
Stuart Kupfer
executiveOkay, here's something I'd like to add: I believe we've gained considerable insight into how to run clinical trials during a pandemic. With respect to METEORIC and REDWOOD-HCM, I'd say we handled those other programs fairly well. That said, there are things we've taken away from the experience, and with COURAGE-ALS, we've built it so that, to the greatest extent we can, it heads off problems tied to pandemic-related disruptions. A big piece of that is having a substantial share of the visits happen at home for patients who sign up for COURAGE-ALS. So we took a very active approach and deliberately shaped this trial to ease the burden on patients. As a result, for the majority of the study visits, they won't actually need to come in person to the clinic; so we saw all of this coming; these elements are built into how the study is designed, and our hope is that this will put us in a good position to handle any additional turbulence in the rev connected to the pandemic.
Graig Suvannavejh
analystI really appreciate the update, and congratulations on how things are going. I was interested in what you said earlier during this call regarding your initial encounters with commercial payers. I think that related to omecamtiv mecarbil. Could you possibly walk us through some of what you learned from that initial experience? Obviously, there's still a fair amount of time remaining, but I'm wondering what the first reactions have been. Then, second, I'd like to understand — and I may have missed this earlier, so I apologize. When you consider how the clinical trial for Aficamten will be designed, in what ways could it resemble or differ from the Mavacamten Phase III, as far as you can anticipate? A lot of us will be attempting to determine how comparable the two really are, and they don't need to be, but I'm just wondering whether you could offer some big-picture thinking on how you're approaching that Phase III trial.
Robert Blum
executiveAbsolutely. I'll have Andrew address the first one, which concerns initial feedback and perspectives involving payers. After that, perhaps I'll turn to Stuart for the second portion of your question, about the trial for Aficamten. Andrew?
Andrew Callos
executiveAbsolutely, Robert. Regarding those payer discussions, we've held roughly six meetings with major PBMs, Med-D, and commercial groups. A majority of those conversations were initial get-togethers, giving them a look at who we are, what our science involves, and the team behind it, and we definitely have deeper engagements lined up as we move further into the year. We also fully expect to submit our filing during December so that Med-D coverage under the 2023 reimbursement and access program can be pursued. So on the whole, these exchanges have gone well, though it's still early.
Robert Blum
executiveYeah. I'd say those meetings are largely about getting the science out there and putting the company on the map; we want to be sure they're aware of us. As you can imagine, they're doing their budgeting and other work in preparation for new product launches, and those efforts are already in motion. Then the second part of what you asked has to do with the Phase III design of Aficamten and how it could stack up against Mavacamten, and whether this ends up being apples and oranges or apples and apples. And I'll tell you, given that REDWOOD-HCM delivered on its next-in-class profile, we think we need to design a study that moves the field forward. So it should be apples and apples, though there are different varieties of apples. With that, let me see if Stuart has anything more to add.
Stuart Kupfer
executiveWhat I can say is that the REDWOOD-HCM trial and the EXPLORER trial have definitely taught us quite a bit, and those lessons will be incorporated into how we design the Phase III study. We aren't in a position right now to provide specifics or go into them at this point. Later this year, the details of the study design will be shared.
Robert Blum
executiveAbsolutely. The wait won't be much longer—those specifics are coming shortly. With the interactions we've just had with FDA now behind us, and once we can finalize the protocol, our expectation is to launch this study before long, and we'll lay out those design elements in detail soon.
Robert Blum
executiveThanks to our operator, and thanks as well to everyone joining us on today’s teleconference; our second quarter has been highly productive, and it positions us for what we hope will be our capacity to keep delivering strongly on additional important milestones and metrics. We appreciate your ongoing backing and your interest in Cytokinetics, and we anticipate bringing you further updates about our advancement. Operator, we can now end the call.
Operator
operatorEveryone, we appreciate your joining us. That brings today's conference call to a close. You're free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.